Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors.
Schrock AB, Madison R, Rosenzweig M, Allen JM, Erlich RL, Wang SY, Chidiac T, Reddy VS, Riess JW, Yassa AE, Shakir A, Miller VA, Alexander BM, Venstrom J, McGregor K, Ali SM.
Schrock AB, et al. Among authors: yassa ae.
Lung Cancer (Auckl). 2020 Apr 17;11:33-39. doi: 10.2147/LCTT.S239675. eCollection 2020.
Lung Cancer (Auckl). 2020.
PMID: 32368168
Free PMC article.